Latest Breaking News On - Mymd pharmaceuticals - Page 6 : comparemela.com

InnovationRx: Babylon Files For Bankruptcy

InnovationRx is your weekly digest of healthcare news. Sign up!

FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA) | Region

BALTIMORE (BUSINESS WIRE) Aug 14, 2023

Form 424B1 MIRA PHARMACEUTICALS,

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

- MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of.

MyMD Pharma Up 9% On Topline Phase 2 Results For Oral TNF-a Inhibitor MYMD-1

Shares of MyMD Pharmaceuticals, Inc. (MYMD) are up 9% on Monday after the company reported that it achieved its primary and secondary endpoints from its randomized Phase 2 study of oral TNF-a inhibitor, MYMD-1 in patients with chronic inflammation associated with sarcopenia, or age-related frailty.